新型载阿霉素纳米粒子制备及其性能研究  

New doxorubicin nanoparticle preparation and its performance study

作　　者：朱婷[1] 谢妮[1] 刘丽桃 姚雨江 方周宾[1] 万丽丽[1] 

机构地区：[1]深圳市第二人民医院,广东深圳518035

出　　处：《热带医学杂志》2016年第1期35-38,F0004,共5页Journal of Tropical Medicine

基　　金：广东省科技计划项目(2014A020212038;2013B021800097);深圳市知识创新计划基础研究项目(JCYJ20150330102720122)

摘　　要：目的制备新型载阿霉素纳米粒子,观察其理化性能,研究其对乳腺癌MDA-MB231细胞凋亡及在裸鼠体内的抑瘤作用,为三阴性乳腺癌的治疗提供依据。方法制备右旋糖苷纳米粒子,构建EGFR-Dextran-DOX纳米材料,Hoechst33258荧光染料及ELISA实验检测MDA-MB231细胞凋亡。将裸鼠随机分为4组,作相应处理后分别注射磷酸缓冲盐溶液(PBS)、阿霉素(DOX)、Dextran-DOX及EGFR-Dextran-DOX,测量各组瘤体大小。结果 EGFR-DextranDOX纳米粒子大小均一,平均粒径98 nm,包封率为77.0%,载药量9.8%。pH值越低,EGFR-Dextran-DOX纳米粒子DOX释放率越高。EGFR-Dextran-DOX处理组的细胞凋亡率及在裸鼠体内的抑瘤作用高于DOX和Dextran-DOX组,差异有统计学意义(P<0.05)。结论成功制备EGFR-Dextran-DOX纳米粒子,制备的纳米粒对三阴性乳腺癌具有靶向抑制作用。Objective To develop a new doxorubicin loaded nanoparticle and observe its physical properties,research its apoptosis of breast cancer MDA-MB231 cells and tumor suppression in nude mice, thus in this way to provide a new basis for triple negative breast cancer （TNBC） treatment. Methods Dextran nanoparticles were prepared in the first place then we established EGFR-Dextran-DOX nanoparticle,and detected MDA-MB231 cell apoptosis with Hoechst33258 fluorescence dye and ELISA, then randomly divided 24 nude mice into 4 groups.After corresponding treatment, different drugs were given, and the tumor size was measured. Results The average size of dox nanoparticles was 98 nm, encapsulation efficiency and drug loading capacity were 77.0% and 9.8%, respectively.In vitro release of dox nonoparticles , the lower the pH, the higher the release rate of dox.Cell apoptosis rate treated by EGFR-Dextran-DOX was higher than which treated with dox and Dextran-Dox, the same result as tumor suppression effect in nude mice, all of them had statistical meaning （P〈0.05）. Conclusion EGFR-Dextran-DOX nanoparticles were successfully developed, which has significant targeted inhibition to TNBC.

关 键 词：阿霉素 纳米粒子 三阴性乳腺癌 靶向治疗 

分 类 号：R737.9[医药卫生—肿瘤]